Commitments And Contingencies (Narrative) (Details) (USD $)	1 Months Ended				12 Months Ended
	May 31, 2017	May 31, 2010	Nov. 30, 2008	May 31, 2007	Dec. 31, 2011 years sqft days	Dec. 31, 2010	Dec. 31, 2009
Commitments And Contingencies [Line Items]
Number of clinical trials			3
Office space under lease, square feet					53,000
Average annual rental expense					$ 1,900,000
Rental agreement expiration date					March 2013
Number of lease renewal options					2
Number of years lease agreement, renewal option					5
Security deposit					1,300,000
Rent expense charged to operations					2,000,000	1,900,000	2,000,000
Number of senior officers with employment agreements					8
Annual employee benefits compensation committed					3,100,000
Severance agreements, aggregate amount					900,000
Amount of unapplied non-refundable fees paid for potential future purchases					1,300,000
Annual product worldwide manufacturing requirement percentage					100.00%
Term of employment agreement, in years					3
Initial advance notice period beginning, date					December 2015
Initial advance notice period ending, date	May 2017				December 2018
Termination of agreement after any written notice, maximum number of days required					30
Notice required to terminate supply agreement, in years					3
Additional increase in term on renewal of purchase contract, years	10
Notice required for termination of service agreement, in days					45
Royalty payments					500,000
Aggregate payment to be made on attaining sales target					800,000
Tax assessment		1,700,000		1,200,000
Settlement including penalty and interest					327,000
Increase in tax assessment due to additional interest and penalties		500,000
Consideration payment per Consulting Agreement					20,000
Number of former employees					2
Bio-Technology General (Israel) Ltd, [Member]
Commitments And Contingencies [Line Items]
Minimum percentage of purchase committed					80.00%
Expected future purchases, 12 months outlook					4,900,000
Non-refundable fees paid for potential future purchases					6,700,000
Fujifilm Diosynth Biotechnologies USA LLC [Member]
Commitments And Contingencies [Line Items]
Additional costs for re-execution of campaign					800,000
NOF Corporation [Member]
Commitments And Contingencies [Line Items]
Expected future purchases, 12 months outlook					12,600,000
Minimum percentage of supply to be made by supplier					75.00%
Percentage of minimum purchase obligation payable on termination					50.00%
Percentage of minimum purchase obligation payable on breach of purchase contract					50.00%
Sigma-Tau PharmaSource, Inc [Member]
Commitments And Contingencies [Line Items]
Expected future purchases, 12 months outlook					1,300,000
Advance notice period for termination of contract prior expiration of term, months					24
Mountain View Pharmaceuticals And Duke University [Member]
Commitments And Contingencies [Line Items]
Maximum period for royalty payments based on net sales, days					60
Percentage of royalty payable on any revenue or other consideration receives from sub-licensees					20.00%
Aggregate milestone payments made on obtaining regulatory approval						800,000
Aggregate payment to be made on attaining sales target					1,000,000
Aggregate payments made on achievement of milestones					2,500,000
Chief Scientist Of The State Of Israel [Member]
Commitments And Contingencies [Line Items]
Royalty payments					900,000
Financial support of research and development					$ 2,600,000
Minimum [Member] | Mountain View Pharmaceuticals And Duke University [Member]
Commitments And Contingencies [Line Items]
Percentage of royalty rate payable on net sales					8.00%
Maximum [Member] | Mountain View Pharmaceuticals And Duke University [Member]
Commitments And Contingencies [Line Items]
Percentage of royalty rate payable on net sales					12.00%